Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1983 Nov;72(5):1622–1628. doi: 10.1172/JCI111121

Concentrations of an activator protein for sphingolipid hydrolysis in liver and brain samples from patients with lysosomal storage diseases.

K Inui, D A Wenger
PMCID: PMC370450  PMID: 6415115

Abstract

The hydrolysis of sphingolipids by lysosomal enzymes requires the presence of additional proteins, which have been called activator proteins. The number of activator proteins, their specificity, exact mechanism of action, and response to a storage process all remain to be determined. In this study, antibodies to an activator protein known to bind sphingolipids and activate the enzymatic hydrolysis of GM1 ganglioside and sulfatide were used to estimate the concentration of this activator protein in small samples of liver and brain from patients with lysosomal storage diseases. By using rocket immunoelectrophoresis, the concentration of cross-reacting material (CRM) was determined. Control livers had an average of 0.95 +/- 0.18 (mean +/- 1 SD) microgram CRM/mg protein in the extracts, and control brains had an average of 0.25 +/- 0.14 microgram CRM/mg protein. Extremely high levels of CRM were found in extracts of livers from patients with type 1 GM1 gangliosidosis (15.1 and 16.9), and type A Niemann-Pick disease (10.7). Extracts of brain samples revealed a large amount of CRM in type 1 GM1 gangliosidosis (14.8), Tay-Sachs disease (5.3 and 8.7), and Sandhoff disease (13.5). Significantly elevated CRM was also measured in brain samples from patients with type 2 GM1 gangliosidosis, type A Niemann-Pick disease, metachromatic leukodystrophy, and Krabbe disease. The highest levels are found in those genetic diseases where the lipids stored, primarily or secondarily to the genetic defect, bind to this activator protein. This activator protein may have an important function in regulating intralysosomal lipid catabolism, and changes in its concentration in certain genetic diseases may be the cause of clinical, biochemical, and pathological heterogeneity found in the patients.

Full text

PDF
1622

Images in this article

1625Image
on p.1625
1625Image
on p.1625
1626Image
on p.1626

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alpert A. J., Beaudet A. L. Apolipoprotein C-III-1 activates lysosomal sphingomyelinase in vitro. J Clin Invest. 1981 Dec;68(6):1592–1596. doi: 10.1172/JCI110414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Burnette W. N. "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 1981 Apr;112(2):195–203. doi: 10.1016/0003-2697(81)90281-5. [DOI] [PubMed] [Google Scholar]
  3. Christomanou H. Niemann-Pick disease, Type C: evidence for the deficiency of an activating factor stimulating sphingomyelin and glucocerebroside degradation. Hoppe Seylers Z Physiol Chem. 1980 Oct;361(10):1489–1502. doi: 10.1515/bchm2.1980.361.2.1489. [DOI] [PubMed] [Google Scholar]
  4. Conzelmann E., Sandhoff K. AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3979–3983. doi: 10.1073/pnas.75.8.3979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fischer G., Jatzkewitz H. The activator of cerebroside sulphatase. Binding studies with enzyme and substrate demonstrating the detergent function of the activator protein. Biochim Biophys Acta. 1977 Apr 12;481(2):561–572. doi: 10.1016/0005-2744(77)90288-1. [DOI] [PubMed] [Google Scholar]
  6. Hechtman P. Characterization of an activating factor required for hydrolysis of Gm2 ganglioside catalyzed by hexosaminidase A. Can J Biochem. 1977 Apr;55(4):315–324. doi: 10.1139/o77-044. [DOI] [PubMed] [Google Scholar]
  7. Hechtman P., Gordon B. A., Ng Ying Kin N. M. Deficiency of the hexosaminidase A activator protein in a case of GM2 gangliosidosis; variant AB. Pediatr Res. 1982 Mar;16(3):217–222. doi: 10.1203/00006450-198203000-00011. [DOI] [PubMed] [Google Scholar]
  8. Ho M. W., O'Brien J. S. Gaucher's disease: deficiency of 'acid' -glucosidase and reconstitution of enzyme activity in vitro. Proc Natl Acad Sci U S A. 1971 Nov;68(11):2810–2813. doi: 10.1073/pnas.68.11.2810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Inui K., Emmett M., Wenger D. A. Immunological evidence for deficiency in an activator protein for sulfatide sulfatase in a variant form of metachromatic leukodystrophy. Proc Natl Acad Sci U S A. 1983 May;80(10):3074–3077. doi: 10.1073/pnas.80.10.3074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Inui K., Grebner E. E., Jackson L. G., Wenger D. A. Juvenile GM2 gangliosidosis (AMB variant): inability to activate hexosaminidase A by activator protein. Am J Hum Genet. 1983 Jul;35(4):551–564. [PMC free article] [PubMed] [Google Scholar]
  11. Inui K., Wenger D. A. Properties of a protein activator of glycosphingolipid hydrolysis isolated from the liver of a patient with GM1 gangliosidosis, type 1. Biochem Biophys Res Commun. 1982 Mar 30;105(2):745–751. doi: 10.1016/0006-291x(82)91497-8. [DOI] [PubMed] [Google Scholar]
  12. Jatzkewitz H., Stinshoff K. An activator of cerebroside sulphatase in human normal liver and in cases of congenital metachromatic leukodystrophy. FEBS Lett. 1973 May 15;32(1):129–131. doi: 10.1016/0014-5793(73)80754-9. [DOI] [PubMed] [Google Scholar]
  13. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  14. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  15. Laurell C. B. Electroimmuno assay. Scand J Clin Lab Invest Suppl. 1972;124:21–37. doi: 10.3109/00365517209102748. [DOI] [PubMed] [Google Scholar]
  16. Li S. C., Hirabayashi Y., Li Y. T. A new variant of type-AB GM2-gangliosidosis. Biochem Biophys Res Commun. 1981 Jul 30;101(2):479–485. doi: 10.1016/0006-291x(81)91285-7. [DOI] [PubMed] [Google Scholar]
  17. Li S. C., Li Y. T. An activator stimulating the enzymic hydrolysis of sphingoglycolipids. J Biol Chem. 1976 Feb 25;251(4):1159–1163. [PubMed] [Google Scholar]
  18. Li S. C., Wan C. C., Mazzotta M. Y., Li Y. T. Requirement of an activator for the hydrolysis of sphingoglycolipids by glycosidases of human liver. Carbohydr Res. 1974 May;34(1):189–193. doi: 10.1016/s0008-6215(00)80383-3. [DOI] [PubMed] [Google Scholar]
  19. Mehl E., Jatzkewitz H. Eine Cerebrosidsulfatase aus Schweineniere. Hoppe Seylers Z Physiol Chem. 1964;339(1):260–276. [PubMed] [Google Scholar]
  20. Shapiro L. J., Aleck K. A., Kaback M. M., Itabashi H., Desnick R. J., Brand N., Stevens R. L., Fluharty A. L., Kihara H. Metachromatic leukodystrophy without arylsulfatase A deficiency. Pediatr Res. 1979 Oct;13(10):1179–1181. doi: 10.1203/00006450-197910000-00021. [DOI] [PubMed] [Google Scholar]
  21. Wenger D. A., Sattler M., Roth S. A protein activator of galactosylceramide beta-galactosidase. Biochim Biophys Acta. 1982 Sep 14;712(3):639–649. doi: 10.1016/0005-2760(82)90293-4. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES